- Technology Management
- For Industry - Technology Available for Licensing
- Contact Technology Management
- old pages
- A Modern Approach to Wing Warp for Aircraft Control
- Treatment Of Liver Fibrosis Following Hepatic Injury By Selective Killing Of Activated Liver Stellate Cells
- Compositions and Methods for Treating and Diagnosing Hepatoma
- Vaccine Compositions and Methods That Increase Safety of Anti-Viral Vaccination Without Loss of Efficacy
- Automatic Pressure-Locking Valve Prevents CSF Loss and Herniation During Lumbar Puncture When Intracranial Pressure Is Elevated.
- Immortal Differentiated Type II Lung Epithelial Cell Line (T7)
- Human A Rapid, Reliable Bedside Diagnostic Method For Accurately Determining Feeding Tube Placement In Respiratory Tract, Stomach, Or Small Bowel Of Patients Prior to Enteral Nutrient Administration.
- Human Natural Killer Cell Line - NK 3.3:
- Factor IXa Protease Helix-330 (Region 1)
- In Vitro Method for Concerted Integration of Donor DNA Molecules Into Target DNA Using Retroviral Integrase and a Procedure for Evaluation of Donor DNA Integration.
- SRCAP: A Novel Transcription Protein Having Therapeutic Target and Diagnostic Target Product Development Potential.
- C-Terminal Binding Protein Interacting Protein (CtIP):
- Novel Anti-Coagulation Therapeutics: Agents That Effectively Inhibit Binding of Factor VIIIa (Region 3) With Factor IXa (Region 2) Without Activating Factor X.
- Genetically Modified Activated Protein C with Reduced Anticoagulant Properties
- C22: A Conditionally Immortalized Mouse Clara Cell Line
Novel Anti-Coagulation Therapeutics: Agents That Effectively Inhibit Binding of Factor VIIIa (Region 3) With Factor IXa (Region 2) Without Activating Factor X.
Inventor: Dr. S. Paul Bajaj and Dr. Philip J. Fay
Two newly discovered areas, factor VIIIa (Region 3) and factor IXa (Region 2), have been identified that interact during factor X activation. Based on a detailed sequence knowledge of factor VIIIa (Region 3) and factor IXa (Region 2), several novel compositions have been identified which effectively inhibiting blood coagulation by blocking the binding of factor VIIIa with factor IXa in the area of Region 2 and/or Region 3 without activating factor X.
These novel coagulation inhibitors include (i) certain polypeptides that contain 3-10 contiguous amino acids (or a nonpeptidomimetic of said amino acids) which are homologous to recognized sequences contained in factor VIIIa (Region 3) or in factor IXa (Region 2), or (ii) a non-homologous binding polypeptide, preferably a humanized monoclonal antibody, having a binding site that specifically binds to factor VIIIa (Region 3) or factor IXa (Region 2), or (iii) a polynucleotide sequence encoding an amino acid sequence homologous to any one of the aforementioned agents where the polynucleotide is operably linked to a control sequence that allows the polynucleotide to be translated in a mammalian cell.
Methods are described for anti-coagulation treatment of patients as well as for the screening and identification of anti-coagulation therapeutic agents that act by effectively blocking the binding of factor VIIIa (Region 3) with factor IXa Region 2).
(1) Novel anti-coagulation therapeutic agents have been identified which bind to newly discovered regions in factor VIIIa (Region 3) and factor IXa (Region 2) and effectively block factor X activation and blood coagulation. These novel coagulation inhibitors are potentially useful therapeutic products targeted to treatment of patients suffering from cardiovascular disorders (thrombosis, atherosclerosis, restenosis); and,
(2) A sensitive in vitro assay procedure is described that is useful for screening of drug candidates for anti-coagulation activity resulting from inhibition of the binding of factor VIIIa (Region 3) with factor IXa (Region 2) without activation of factor X.
Keywords: anticoagulant, factor X activation, blood clotting, fibrinolysis, hemophilia, factor VIII, factor IX, hemostasis
Patents: PCT Application US/02/01724 (Filed Jan 23,2002): Designating US
Reference Number: SLU-1003